Long-Term Haematological and Renal Toxicity of 90Yttrium-DOTA-Octreotate in the Treatment of Advanced Neuroendocrine Tumors(NETs) Abstract #768

Introduction: Peptide receptor radiation therapy (PRRT) is an established treatment for advanced NETs. Renal/haematological toxicity are recognised adverse effects.
Aim(s): To assess the long-term toxicity of PRRT with Yttrium90-tyr3-DOTA-octreotate in progressive NETs.
Materials and methods: Two-hundred and thirty-five patients receiving 2.9-3.3 GBq/treatment cycle (with prophylactic aminoacid infusion) were included. Weekly serology was performed for eight weeks post cycle. Median 24 month follow-up results were analysed. Bone marrow (BMT) and renal (RT) toxicity patients were grouped according to severity: A (WHO grade 1-2) and B (grade 3-4).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: DR VINCENT Cheung

To read results and conclusion, please login ...

Further abstracts you may be interested in

#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Giovanni Paganelli
#698 Feasability of a Dosimetry Guided Therapy Planning for Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-Octreotate
Introduction: The efficacy and safety profile of PRRT can theoretically be optimized by planning each individual patient treatment on the absorbed dose to the critical organs and tumor lesions.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: PhD Mark W Konijnenberg
Keywords: PRRT, dosimetry
#889 Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)
Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Olivia Hentic
#932 Hematological Toxicity of Combined Lutetium-177 Octreotate Radiopeptide-Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors Followed Long-Term
Introduction: Combination radiopeptide therapy (PRRT) with radiosensitizing chemotherapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs) may improve efficacy, but has the potential to increase myelotoxicity.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Murali Kesavan
Keywords: PRRT, GEP-NET